Figure 4. Concentration response curves (CRCs) for ML395 in both A) a cellular assay (PMA-stimulated Calu-1 cells and a basal HEK293-gfpPLD2 stabkle cell line) with cellular PLD2, IC50 = 360 nM and cellular PLD1, IC50 >30,000 nM, and B) a biochemical assay with purified PLD2 (biochemical PLD2, IC50 = 8,700 nM) and PLD1 (biochemical PLD1, IC50 >30,000 nM).

Figure 4Concentration response curves (CRCs) for ML395 in both A) a cellular assay (PMA-stimulated Calu-1 cells and a basal HEK293-gfpPLD2 stabkle cell line) with cellular PLD2, IC50 = 360 nM and cellular PLD1, IC50 >30,000 nM, and B) a biochemical assay with purified PLD2 (biochemical PLD2, IC50 = 8,700 nM) and PLD1 (biochemical PLD1, IC50 >30,000 nM)

From: A Next generation PLD2 inhibitor with improved physiochemical properties and DMPK profile for translational in vivo

Cover of Probe Reports from the NIH Molecular Libraries Program
Probe Reports from the NIH Molecular Libraries Program [Internet].

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.